Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.218033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Maria Urbanova und 23 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Aurora Kinase A, Carcinoma, Neuroendocrine, Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Cooperation in Science and Technology, Slovak Academy of Sciences, Instituto de Salud Carlos III.
Abstract (Originalsprache)
Chemotherapy with cisplatin (CDDP) and etoposide (ETO) is the standard treatment for gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). Despite high initial response rates, treatment-related toxicity and acquired resistance remain significant clinical challenges. No molecularly targeted therapies are currently established for this aggressive cancer. Here, we evaluated Aurora kinase inhibition with alisertib (ALI) as a synthetic lethality strategy in ARID1A-deficient GEP-NEC. Subcutaneous and orthotopic xenograft models were established in immunodeficient mice using the GEP-NEC-derived NT-38 cell line, and the therapeutic efficacy of ALI was compared with CDDP + ETO. Tumor responses were assessed by immunohistochemistry, Western blotting, and RNA sequencing. To confirm ARID1A dependency, transient knockdown was induced in the pancreatic neuroendocrine NT-18LM cell line, demonstrating that ALI sensitivity is significantly enhanced in ARID1A-deficient cells. ALI achieved antitumor efficacy comparable to chemotherapy and was well tolerated, with minimal weight loss relative to CDDP + ETO. Distant metastases, an early feature of GEP-NEC, developed in five animals over six weeks, two of which were treated with ALI and three controls. Transcriptomic profiling revealed convergence of both treatments on signal transduction, focal adhesion, receptor tyrosine kinase, and VEGFA-VEGFR2 signaling, while ALI uniquely enriched pathways related to pancreatic secretion, lipid metabolism, protein processing in the endoplasmic reticulum, and extracellular matrix organization. These findings establish Aurora kinase inhibition as mechanistically distinct and selectively effective in ARID1A-deficient GEP-NEC. Given its efficacy, favorable tolerability, and ARID1A-dependent specificity, ALI may represent a promising alternative to platinum-based chemotherapy, offering a strong rationale for further development of mechanism-driven combination strategies for GEP-NEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Research Center, Slovak Academy of Sciences, 845 05 Bratislava, Slovakia.
- Medical Department, University Medical Center Hamburg-Eppendorf, D-20246, Hamburg, Germany; Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg Eppendorf, 20246, Hamburg, Germany. Electronic…
- Ramón y Cajal Health Research Institute (IRYCIS), Ramón y Cajal University Hospital. Ctra. Colmenar Viejo, 28034, Madrid, Spain; Department of Cancer, Instituto de Investigaciones Biomedicas Sols-Morreale (IIBM), CSIC-U…
- Department of Pathology, Hippokration General, Hospital of Athens, Athens, 11527, Greece.
- Latvian Biomedical Research and Study Centre, Ratsupites Str 1-k1, LV-1067, Riga, Latvia.
- Ramón y Cajal Health Research Institute (IRYCIS), Ramón y Cajal University Hospital. Ctra. Colmenar Viejo, 28034, Madrid, Spain.
Förderung
- European Cooperation in Science and Technology
- Slovak Academy of Sciences
- Instituto de Salud Carlos III
- General Secretariat for Research and Innovation
- EU Framework Programme for Research and Innovation Spreading Excellence and Widening Participation
- Werner Otto Stiftung
- Ministry of National Education and Religious Affairs
- Horizon 2020 Framework Programme
Zitieren
APA
Urbanova, M., Viol, F., Ruiz-Cañas, L., Koniaris, E., Saksis, R., Batres-Ramos, S., Earl, J., Kataki, A., Buocikova, V., Burikova, M., Cihova, M., Rojikova, L., Makovicky, P., Matuskova, M., Kohl, Y., Riedmayer, A., Makova, M., Baciak, L., Gogola, D., …, & Schrader, J. (2025). Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.218033
Vancouver
Urbanova M, Viol F, Ruiz-Cañas L, Koniaris E, Saksis R, Batres-Ramos S, et al. Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.218033
BibTeX
@article{Urbanova2025,
author = {Urbanova, Maria and Viol, Fabrice and Ruiz-Cañas, Laura and Koniaris, Efthymios and Saksis, Rihards and Batres-Ramos, Sandra and Earl, Julie and Kataki, Agapi and Buocikova, Verona and Burikova, Monika and Cihova, Marina and Rojikova, Lucia and Makovicky, Peter and Matuskova, Miroslava and Kohl, Yvonne and Riedmayer, Andrea and Makova, Marianna and Baciak, Ladislav and Gogola, Daniel and Rogoza, Olesja and Rovite, Vita and Sainz, Bruno and Smolkova, Bozena and Schrader, Joerg},
title = {Aurora kinase A inhibition as a synthetic lethality strategy in ARID1A-mutated gastroenteropancreatic neuroendocrine carcinoma},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.218033}
}
EUVIMED